首頁 > 市場調查報告書 > 醫療設備

泌尿科

市場調查報告書

商品編碼

1506299

尿失禁:市場洞察·流行病學·市場預測 (～2034年)

Urinary Incontinence - Market Insight, Epidemiology, and Market Forecast - 2034

出版日期: 2024年06月01日 | 出版商:

DelveInsight | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

本報告提供全球主要7個國家尿失禁的市場調查，彙整疾病的背景·概要，流行病學，治療和管理概要，推動市場要素與阻礙，未滿足需求，上市藥及開發平台藥物的簡介，主要國家的市場規模的轉變·預測，競爭情形等資料，以及最好的機會，評價市場潛在力等資訊。

對象地區

美國
歐洲5個國家(德國·法國·義大利·西班牙·英國)
日本

調查期間:2020年～2034年

報告要點

由於人們對該疾病的認識不斷提高以及全球醫療保健支出的增加，預計未來幾年尿失禁市場將出現變化。
公司和研究機構正在努力分析可能影響尿失禁研究和開發的課題並探索機會。正在開發的療法著重於治療/改善疾病狀況的新方法。
各大公司正致力於開發治療尿失禁的藥物。新治療藥物的推出預計將對市場產生重大影響。
開發尿失禁的新療法需要更深入地了解疾病病理學。
依開發階段（第三階段和第二階段）對我們的管道資產進行深入分析，包括各種新興趨勢、詳細的臨床概況、關鍵交叉競爭、上市日期和產品線藥物開發活動比較分析，為客戶提供協助。

DelveInsight's "Urinary Incontinence - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Urinary Incontinence, historical and forecasted epidemiology as well as the Urinary Incontinence market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Urinary Incontinence market report provides current treatment practices, emerging drugs, Urinary Incontinence market share of the individual therapies, current and forecasted Urinary Incontinence market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Urinary Incontinence treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2020-2034

Urinary Incontinence Disease Understanding and Treatment Algorithm

The DelveInsight Urinary Incontinence market report gives a thorough understanding of the Urinary Incontinence by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Urinary Incontinence.

Treatment

It covers the details of conventional and current medical therapies available in the Urinary Incontinence market for the treatment of the condition. It also provides Urinary Incontinence treatment algorithms and guidelines in the United States, Europe, and Japan.

Urinary Incontinence Epidemiology

The Urinary Incontinence epidemiology division provide insights about historical and current Urinary Incontinence patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Urinary Incontinence epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Urinary Incontinence Epidemiology

The epidemiology segment also provides the Urinary Incontinence epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Urinary Incontinence Drug Chapters

Drug chapter segment of the Urinary Incontinence report encloses the detailed analysis of Urinary Incontinence marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Urinary Incontinence clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Urinary Incontinence treatment.

Urinary Incontinence Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Urinary Incontinence treatment.

Urinary Incontinence Market Outlook

The Urinary Incontinence market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Urinary Incontinence market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Urinary Incontinence market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Urinary Incontinence market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Urinary Incontinence market in 7MM.

The United States Market Outlook

This section provides the total Urinary Incontinence market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Urinary Incontinence market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Urinary Incontinence market size and market size by therapies in Japan is also mentioned.

Urinary Incontinence Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Urinary Incontinence market or expected to get launched in the market during the study period 2020-2034. The analysis covers Urinary Incontinence market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Urinary Incontinence Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Urinary Incontinence key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Urinary Incontinence emerging therapies.

Reimbursement Scenario in Urinary Incontinence

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Urinary Incontinence domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Urinary Incontinence market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Urinary Incontinence Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Urinary Incontinence, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Urinary Incontinence epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Urinary Incontinence are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Urinary Incontinence market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Urinary Incontinence market

Report Highlights:

In the coming years, Urinary Incontinence market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Urinary Incontinence R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Urinary Incontinence. Launch of emerging therapies will significantly impact the Urinary Incontinence market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Urinary Incontinence
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Urinary Incontinence Report Insights

Patient Population
Therapeutic Approaches
Urinary Incontinence Pipeline Analysis
Urinary Incontinence Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Urinary Incontinence Report Key Strengths

11 Years Forecast
7MM Coverage
Urinary Incontinence Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Urinary Incontinence Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions:

Market Insights:

What was the Urinary Incontinence market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Urinary Incontinence total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Urinary Incontinence market size during the forecast period (2024-2034)?
At what CAGR, the Urinary Incontinence market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Urinary Incontinence market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Urinary Incontinence market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Urinary Incontinence?
What is the historical Urinary Incontinence patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Urinary Incontinence in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Urinary Incontinence?
Out of all 7MM countries, which country would have the highest prevalent population of Urinary Incontinence during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Urinary Incontinence treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Urinary Incontinence in the USA, Europe, and Japan?
What are the Urinary Incontinence marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Urinary Incontinence?
How many therapies are developed by each company for Urinary Incontinence treatment?
How many are emerging therapies in mid-stage, and late stage of development for Urinary Incontinence treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Urinary Incontinence therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Urinary Incontinence and their status?
What are the key designations that have been granted for the emerging therapies for Urinary Incontinence?
What are the global historical and forecasted market of Urinary Incontinence?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving the Urinary Incontinence market
To understand the future market competition in the Urinary Incontinence market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Urinary Incontinence in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Urinary Incontinence market
To understand the future market competition in the Urinary Incontinence market

1. Key Insights

2. Executive Summary of Urinary Incontinence

3. Competitive Intelligence Analysis for Urinary Incontinence

4. Urinary Incontinence: Market Overview at a Glance

4.1. Urinary Incontinence Total Market Share (%) Distribution in 2020
4.2. Urinary Incontinence Total Market Share (%) Distribution in 2034

5. Urinary Incontinence: Disease Background and Overview

5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Urinary Incontinence Epidemiology and Patient Population

7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
- 7.3.1. Urinary Incontinence Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
- 7.4.1. Urinary Incontinence Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
  - 7.5.1.1. Urinary Incontinence Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
  - 7.5.2.1. Urinary Incontinence Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
  - 7.5.3.1. Urinary Incontinence Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
  - 7.5.4.1. Urinary Incontinence Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
  - 7.5.5.1. Urinary Incontinence Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
  - 7.5.6.1. Urinary Incontinence Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Urinary Incontinence Treatment and Management
8.2. Urinary Incontinence Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Urinary Incontinence Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross
12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile

List to be continued in report

13. Urinary Incontinence: Seven Major Market Analysis

13.1. Key Findings
13.2. Urinary Incontinence Market Size in 7MM
13.3. Urinary Incontinence Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size
- 15.1.1. Urinary Incontinence Total Market Size in the United States
- 15.1.2. Urinary Incontinence Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
- 15.3.1. Urinary Incontinence Total Market Size in Germany
- 15.3.2. Urinary Incontinence Market Size by Therapies in Germany
15.4. France Market Size
- 15.4.1. Urinary Incontinence Total Market Size in France
- 15.4.2. Urinary Incontinence Market Size by Therapies in France
15.5. Italy Market Size
- 15.5.1. Urinary Incontinence Total Market Size in Italy
- 15.5.2. Urinary Incontinence Market Size by Therapies in Italy
15.6. Spain Market Size
- 15.6.1. Urinary Incontinence Total Market Size in Spain
- 15.6.2. Urinary Incontinence Market Size by Therapies in Spain
15.7. United Kingdom Market Size
- 15.7.1. Urinary Incontinence Total Market Size in the United Kingdom
- 15.7.2. Urinary Incontinence Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
- 15.8.1. Japan Market Size
- 15.8.2. Urinary Incontinence Total Market Size in Japan
- 15.8.3. Urinary Incontinence Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Urinary Incontinence

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography
20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

簡介目錄圖表

List of Tables

Table 1: 7MM Urinary Incontinence Epidemiology (2020-2034)
Table 2: 7MM Urinary Incontinence Diagnosed and Treatable Cases (2020-2034)
Table 3: Urinary Incontinence Epidemiology in the United States (2020-2034)
Table 4: Urinary Incontinence Diagnosed and Treatable Cases in the United States (2020-2034)
Table 5: Urinary Incontinence Epidemiology in Germany (2020-2034)
Table 6: Urinary Incontinence Diagnosed and Treatable Cases in Germany (2020-2034)
Table 7: Urinary Incontinence Epidemiology in France (2020-2034)
Table 8: Urinary Incontinence Diagnosed and Treatable Cases in France (2020-2034)
Table 9: Urinary Incontinence Epidemiology in Italy (2020-2034)
Table 10: Urinary Incontinence Diagnosed and Treatable Cases in Italy (2020-2034)
Table 11: Urinary Incontinence Epidemiology in Spain (2020-2034)
Table 12: Urinary Incontinence Diagnosed and Treatable Cases in Spain (2020-2034)
Table 13: Urinary Incontinence Epidemiology in the UK (2020-2034)
Table 14: Urinary Incontinence Diagnosed and Treatable Cases in the UK (2020-2034)
Table 15: Urinary Incontinence Epidemiology in Japan (2020-2034)
Table 16: Urinary Incontinence Diagnosed and Treatable Cases in Japan (2020-2034)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
Table 20: Region-wise Market Size in USD, Million (2020-2034)
Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
Table 22: United States Market Size in USD, Million (2020-2034)
Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
Table 24: Germany Market Size in USD, Million (2020-2034)
Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
Table 26: France Market Size in USD, Million (2020-2034)
Table 27: France Market Size by Therapy in USD, Million (2020-2034)
Table 28: Italy Market Size in USD, Million (2020-2034)
Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
Table 30: Spain Market Size in USD, Million (2020-2034)
Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
Table 32: United Kingdom Market Size in USD, Million (2020-2034)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
Table 34: Japan Market Size in USD, Million (2020-2034)
Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Urinary Incontinence Epidemiology (2020-2034)
Figure 2: 7MM Urinary Incontinence Diagnosed and Treatable Cases (2020-2034)
Figure 3: Urinary Incontinence Epidemiology in the United States (2020-2034)
Figure 4: Urinary Incontinence Diagnosed and Treatable Cases in the United States (2020-2034)
Figure 5: Urinary Incontinence Epidemiology in Germany (2020-2034)
Figure 6: Urinary Incontinence Diagnosed and Treatable Cases in Germany (2020-2034)
Figure 7: Urinary Incontinence Epidemiology in France (2020-2034)
Figure 8: Urinary Incontinence Diagnosed and Treatable Cases in France (2020-2034)
Figure 9: Urinary Incontinence Epidemiology in Italy (2020-2034)
Figure 10: Urinary Incontinence Diagnosed and Treatable Cases in Italy (2020-2034)
Figure 11: Urinary Incontinence Epidemiology in Spain (2020-2034)
Figure 12: Urinary Incontinence Diagnosed and Treatable Cases in Spain (2020-2034)
Figure 13: Urinary Incontinence Epidemiology in the UK (2020-2034)
Figure 14: Urinary Incontinence Diagnosed and Treatable Cases in the UK (2020-2034)
Figure 15: Urinary Incontinence Epidemiology in Japan (2020-2034)
Figure 16: Urinary Incontinence Diagnosed and Treatable Cases in Japan (2020-2034)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
Figure 20: Region-wise Market Size in USD, Million (2020-2034)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
Figure 22: United States Market Size in USD, Million (2020-2034)
Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
Figure 24: Germany Market Size in USD, Million (2020-2034)
Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
Figure 26: France Market Size in USD, Million (2020-2034)
Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
Figure 28: Italy Market Size in USD, Million (2020-2034)
Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
Figure 30: Spain Market Size in USD, Million (2020-2034)
Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
Figure 34: Japan Market Size in USD, Million (2020-2034)
Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)